Johnson Fistel Investigates TransMedics Group, Inc. (TMDX) After Recent Disclosures Concerning Margin Pressure and NOP Investments

SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating TransMedics Group, Inc. (NASDAQ: TMDX) on behalf of investors who suffered losses and whether those losses may be recoverable under federal securities laws.

GlobeNewsWire • Jun 12, 2026

TransMedics: Why I'm Still Bullish After The Collapse

TransMedics (TMDX) faces decelerating revenue growth, margin pressure, and increased investment, yet maintains strong market share gains and competitive positioning. TMDX's logistics and clinical services now comprise nearly 40% of revenue, enhancing competitive advantages and supporting long-term margin strength. Despite growth normalizing to 20-25% and compressed margins, I see current valuation at 4x EV/Sales as attractive, supporting a Buy rating.

Seeking Alpha • Jun 9, 2026

3 Growth Stocks Worth $5,000 of Your Money -- Even in This Market

Credo is evolving into a full-stack AI connectivity leader through silicon photonics. Cellebrite's recurring revenue and government ties create a powerful competitive moat.

The Motley Fool • Jun 5, 2026

TransMedics (TMDX) Down 4.4% Since Last Earnings Report: Can It Rebound?

TransMedics (TMDX) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026

This Healthcare Infrastructure Stock Is Risky, But the Upside Looks Huge

TransMedics (TMDX +1.19%) has been hit hard as investors question margins, spending, and execution. But beneath the sell-off, the company's Organ Care System, aviation network, and National OCS Program could be building a deeper transplant infrastructure moat than the market realizes.

The Motley Fool • Jun 2, 2026

Reasons to Retain TransMedics Stock in Your Portfolio for Now

TMDX is advancing its OCS platform and transplant ecosystem, but margin pressure from expansion investments remains a key concern.

Zacks Investment Research • May 28, 2026

TransMedics: Despite Earnings Miss, Growth Story Remains Intact

TransMedics remains a 'Strong Buy' despite a 50% stock decline and Q1 2026 earnings miss, supported by robust long-term growth initiatives. TMDX's portfolio expansion includes CHOPS as a complementary offering and aggressive European NOP rollout, aiming to expand its addressable market. Q1 2026 revenue grew 21% year-over-year to $174 million, led by liver segment strength, though higher costs compressed margins and net income.

Seeking Alpha • May 25, 2026

TransMedics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

ANDOVER, Mass., May 21, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced that on May 19, 2026, TransMedics granted non-qualified stock options to purchase an aggregate of 37,367 shares of its common stock and an aggregate of 24,848 restricted stock units to 14 employees, each as a material inducement for each employee's entry into employment with TransMedics.

PRNewsWire • May 21, 2026

TransMedics to Present at the William Blair 46th Annual Growth Stock Conference

ANDOVER, Mass., May 19, 2026 /PRNewswire/ -- TransMedics Group, Inc. ("TransMedics") (Nasdaq: TMDX), a medical technology company that is transforming organ transplant therapy for patients with end-stage lung, heart, and liver failure, today announced the company will be participating in the William Blair 46th Annual Growth Stock Conference in Chicago on Tuesday, June 2, 2026.

PRNewsWire • May 19, 2026

TMDX Dips After Posting Q1 Earnings & Revenue Miss, Margins Fall

TransMedics' Q1 revenues rise 21% on strong OCS demand, but a sharp EPS miss and margin pressure send shares down despite continued logistics growth.

Zacks Investment Research • May 6, 2026